{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-103722","form_type":"8-K","ticker":"GKOS","cik":"0001192448","company_name":"GLAUKOS Corp","filed_at":"2025-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.946971+00:00","generated_at":"2026-05-17T01:35:05.967323+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Glaukos Q3 revenue $133.5M (+38% YoY); raises 2025 guide, introduces 2026 outlook","bullets":["Record net sales $133.5M, up 38% YoY; U.S. Glaucoma sales $80.8M (+57% YoY).","GAAP net loss $16.2M (($0.28)/share) improved from $21.4M loss prior year; non-GAAP loss $9.2M (($0.16)/share).","Raised FY2025 net sales guidance to $490-495M (from $480-486M); introduced preliminary FY2026 guidance $600-620M.","Gross margin ~78% (non-GAAP ~84%); ended quarter with $277.5M cash, no debt."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-103722","json":"https://secwatch.observer/filing/0001104659-25-103722.json","markdown":"https://secwatch.observer/filing/0001104659-25-103722.md","text":"https://secwatch.observer/filing/0001104659-25-103722.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1192448/000110465925103722/0001104659-25-103722-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1192448/000110465925103722/gkos-20251029x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:35:05.967323+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}